Thyroid Hormone Replacement Therapy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Thyroid hormone replacement has been used for more than 100 years in the treatment of hypothyroidism, and there is no doubt about its overall efficacy. Desiccated thyroid contains both thyroxine (T4) and triiodothyronine (T3); serum T3 frequently rises to supranormal values in the absorption phase, associated with palpitations. Liothyronine (T3) has the same drawback and requires twice-daily administration in view of its short half-life. Synthetic levothyroxine (L-T4) has many advantages: in view of its long half-life, once-daily administration suffices, the occasional missing of a tablet causes no harm, and the extrathyroidal conversion of T4 into T3 (normally providing 80% of the daily T3 production rate) remains fully operative, which may have some protective value during illness. Consequently, L-T4 is nowadays preferred, and its long-term use is not associated with excess mortality. The mean T4 dose required to normalize serum thyroid stimulating hormone (TSH) is 1.6 µg/kg per day, giving rise to serum free T4 (fT4) concentrations that are slightly elevated or in the upper half of the normal reference range. The higher fT4 values are probably due to the need to generate from T4 the 20% of the daily T3 production rate that otherwise is derived from the thyroid gland itself. The daily maintenance dose of T4 varies widely between 75 and 250 µg. Assessment of the appropriate T4 dose is by assay of TSH and fT4, preferably in a blood sample taken before ingestion of the subsequent T4 tablet. Dose adjustments can be necessary in pregnancy and when medications are used that are known to interfere with the absorption or metabolism of T4. A new equilibrium is reached after approximately 6 weeks, implying that laboratory tests should not be done earlier. With a stable maintenance dose, an annual check-up usually suffices. Accumulated experience with L-T4 replacement has identified some areas of concern. First, the bioequivalence sometimes differs among generics and brand names. Second, many patients on T4 replacement have a subnormal TSH. TSH values of ≤0.1 mU/l carry a risk of development of atrial fibrillation and are associated with bone loss although not with a higher fracture rate. It is thus advisable not to allow TSH to fall below – arbitrarily – 0.2 mU/l. Third, recent animal experiments indicate that only the combination of T4 and T3 replacement, and not T4 alone, ensures euthyroidism in all tissues of thyroidectomized rats. It is indeed the experience of many physicians that there exists a small subset of hypothyroid patients who, despite biochemical euthyroidism, continue to complain of tiredness, lack of energy, discrete cognitive disorders and mood disturbances. As organs vary in the extent to which their T3 content is derived from serum T3 or locally produced T3 from T4, these complaints may have a biologic substrate; for example, brain T3 content is largely determined by local deiodinase type II activity. Against this background it is of interest that a number of psychometric scores improved significantly in hypothyroid patients upon substitution of 50 µg of their T4 replacement dose by 12.5 µg T3. Confirmatory studies on this issue are urgently awaited. It could well be that a slow-release preparation containing both T4 and T3 might improve the quality of life, compared with T4 replacement alone, in some hypothyroid patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259 · cited 1×
“Cardiac Effects Cardiac effects of long-term TSH-suppressive therapy with L-T 4 have been evaluated in a number of studies. TSH values of ≤0.1 mU/l carry a risk of development of atrial fibrillation [”
BackgroundInfluentialBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482
Treatment Guidelines for Patients With Hyperthyroidism and Hypothyroidism
Singer, P. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520340064038 · Cited by 427
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis
Uzzan, B., Campos, J., Cucherat, M., Nony, P., Boissel, J. P., & Perret, G. Y. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954028 · Cited by 398
Biondi, B. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.12.4701 · Cited by 356
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353
Levothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Increased need for thyroxine in women with hypothyroidism during estrogen therapy
Arafah, B. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442302 · Cited by 267 · cited 1×
“It is therefore recommended to obtain blood samples before taking the next L-T 4 dose. One should aim at TSH values in the lower normal range or just below normal, but avoiding TSH values of ≤0.1 mU/l (see below). Slightly high serum fT 4 concentrations are allowed, but free T 3 (fT 3 ) values should be within the nor…”
BackgroundInfluentialEscobar-Morreale, H. F., del Rey, F. E., Obregón, M. J., & de Escobar, G. M. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641203 · Cited by 261 · cited 1×
“The majority of the daily T 3 production rate is derived from extrathyroidal sources by 5′-deiodination of T 4 . The liver is apparently the main site of T 3 production and contributes significantly to plasma T 3 (fig. 1 ). 1 Fig. 1. Daily production rates of thyroid hormone in healthy adults weighing 70 kg. F01 The a…”
BackgroundBioequivalence of Generic and Brand-name Levothyroxine Products in the Treatment of Hypothyroidism
Dong, B. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540390035032 · Cited by 185 · cited 1×
“Overall, generic and brand name L-T 4 preparations are bioequivalent and interchangeable in the majority of patients receiving L-T 4 replacement therapy [”
BackgroundPilo, A., Iervasi, G., Vitek, F., Ferdeghini, M., Cazzuola, F., & Bianchi, R. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.4.e715 · Cited by 185
Ferretti, E., Persani, L., Jaffrain-Rea, M.-L., Giambona, S., Tamburrano, G., & Beck-Peccoz, P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5553 · Cited by 134
Smith, R. N., Taylor, S. A., & Massey, J. C. (1970) · BMJ · doi:10.1136/bmj.4.5728.145 · Cited by 106 · cited 1×
“Synthetic Liothyronine Sodium (T 3 ) Synthetic liothyronine sodium (T 3 ), despite its superior absorption from the gastrointestinal tract compared with L-T 4 (table 1 ), is not used in thyroid hormone replacement therapy except under exceptional circumstances, such as in myxoedema coma or in thyroid cancer patients i…”
Lean Body Mass is a Predictor of the Daily Requirement for Thyroid Hormone in Older Men and Women
CUNNINGHAM, J. J., & BARZEL, U. S. (1984) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1984.tb02003.x · Cited by 80
Morbidity, Mortality, and Quality of Life for Patients Treated With Levothyroxine
Petersen, K. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390210063015 · Cited by 69 · cited 1×
“and to avoid TSH levels of ≤0.1 mU/l. Available data from a population-based study of 1,462 middle-aged women followed up for 12 years indicate no increased mortality or morbidity in women receiving L-T 4 compared with those without thyroid disease [”
MethodInfluentialMonitoring Therapy in Patients Taking Levothyroxine
Helfand, M., & Crapo, L. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-6-450 · Cited by 62
Thyroid Hormone Levels Affected by Time of Blood Sampling in Thyroxine-Treated Patients
AIN, K. B., PUCINO, F., SHIVER, T. M., & BANKS, S. M. (1993) · Thyroid · doi:10.1089/thy.1993.3.81 · Cited by 56
Olveira, G., Almaraz, M. C., Soriguer, F., Garriga, M. J., Gonzalez‐Romero, S., Tinahones, F., & Ruiz de Adana, M. S. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1961006.x · Cited by 16
Cited by
Hashimoto thyroiditis: Clinical and diagnostic criteria
Caturegli, P., De Remigis, A., & Rose, N. R. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.007 · Cited by 1,057
Ralli, M., Angeletti, D., Fiore, M., D'Aguanno, V., Lambiase, A., Artico, M., de Vincentiis, M., & Greco, A. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102649 · Cited by 600
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329
Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307
“The question whether a subgroup of hypothyroid patients requires a more physiological treatment is still not answered and requires further studies [29,30,31].”
Walsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Metadata
- Authors
- Wiersinga, W. M.
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 56
- Issue
- Suppl. 1
- Pages
- 74-81
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- OpenAlex
- W2165735056
- Cited by
- 148
- References
- 19
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.